Eli LillyLLY
Briefing quotidien des marchés
Ce briefing n’est pas encore disponible dans cette langue — version anglaise affichée.
Dernier briefing
Eli Lilly's stock declines 3.57% amid profit-taking and reimbursement concerns.
Eli Lilly's stock experienced a 3.57% decline on August 26, 2026, as investors engaged in profit-taking following recent gains. Additionally, concerns over corporate and commercial health plan reimbursements for obesity treatments have emerged, potentially impacting future revenue streams.
Briefings précédents
Danske Bank increases Eli Lilly stake by 0.9%, now holding 767,326 shares valued at $920.4 million.
Danske Bank A/S has raised its holdings in Eli Lilly by 0.9%, now owning 767,326 shares valued at approximately $920.4 million. This move reflects institutional confidence in Eli Lilly's performance. Additionally, Eli Lilly's stock price closed at $1,233.66 on August 25, 2026, down $13.27 (-1.06%) from the previous day.
Eli Lilly's stock slips 0.8% to $1,245.68 amid mixed news.
Eli Lilly's stock experienced a slight decline of 0.8%, closing at $1,245.68. This movement occurred despite the FDA's clearance of the Elecsys pTau217 Alzheimer's biomarker blood test and the launch of its oral GLP-1 pill, Foundayo, in UK pharmacies. Both developments were largely anticipated by the market, leading to a muted stock response.
Eli Lilly's stock price reaches $1,255.40, nearing Wall Street's $1,311 target.
Eli Lilly's stock has surged, closing at $1,255.40, just 4.43% below Wall Street's consensus target of $1,311. This rise is attributed to strong second-quarter sales of Mounjaro and Zepbound, which together generated $14.87 billion. Analysts are now focusing on factors like price realization and competition from oral drugs.
Eli Lilly's Q2 2026 revenue surges 48%, raising full-year guidance to $85–87 billion.
Eli Lilly reported a 48% increase in Q2 2026 revenue, driven by strong sales of Mounjaro and Zepbound. The company raised its full-year revenue guidance to $85–87 billion, up from the previous estimate of $82.5–84.5 billion. Additionally, Lilly secured a licensing agreement with OmniAb valued at up to $370 million in milestone payments.
Eli Lilly's stock rises 1.52% to $1,263.34 amid new vaccine collaboration
Eli Lilly's stock increased by 1.52% to $1,263.34 on August 21, 2026, following the announcement of a new collaboration with Amplitude Therapeutics to develop trans-amplifying RNA vaccines for infectious diseases. This partnership is expected to leverage Lilly's global development and commercialization capabilities, potentially enhancing its vaccine portfolio.
Eli Lilly's stock rises 4.7% to $1,283.09 after strong Q2 earnings report.
Eli Lilly's stock surged 4.7% to $1,283.09 following a robust Q2 earnings report, with revenue up 48% to $23 billion, driven by Mounjaro and Zepbound sales. The company also raised its full-year revenue guidance to $85–87 billion.
Eli Lilly's stock rises 3.19% on August 18, outperforming competitors.
Eli Lilly's stock experienced a 3.19% increase on August 18, closing at $1,225.73, outperforming competitors like Johnson & Johnson and Pfizer. This positive movement is attributed to strong demand for its tirzepatide-based treatments, Mounjaro for type 2 diabetes and Zepbound for weight management, which continue to surpass market expectations. Additionally, upward earnings estimate revisions from analysts have further supported the upward trajectory.
No significant market-moving news for Eli Lilly (LLY) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The company continues to benefit from strong demand for its weight-loss and diabetes medications, Mounjaro and Zepbound, which have been key drivers of its recent growth. Additionally, Eli Lilly's dividend growth streak remains intact, with a 15.3% increase announced in December 2025.
No significant market-moving news for Eli Lilly (LLY) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The company continues to focus on its core therapeutic areas, including diabetes, oncology, immunology, and neuroscience. Investors are advised to monitor upcoming earnings reports and regulatory updates for potential market-moving events.
No significant market-moving news for Eli Lilly (LLY) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The company continues to maintain a strong position in the pharmaceutical industry, with recent positive financial results and ongoing advancements in its product pipeline.
No significant market-moving news for Eli Lilly in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The company continues to monitor ongoing litigation related to its GLP-1 receptor agonist drugs, including Ozempic and Mounjaro. Additionally, Eli Lilly is preparing for upcoming earnings reports and potential regulatory decisions on its pipeline products.
No significant market-moving news for Eli Lilly (LLY) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The company continues to focus on its ongoing initiatives, including the expansion of its obesity treatment portfolio and the global rollout of its Alzheimer's disease medication, Kisunla. Traders should monitor upcoming earnings reports and regulatory updates for potential catalysts.
Eli Lilly's stock drops 0.85% to $1,209 amid market fluctuations.
In the past 24 hours, Eli Lilly's stock experienced a slight decline of 0.85%, closing at $1,209. This movement aligns with broader market trends and does not reflect any significant company-specific developments.
No significant market-moving news for Eli Lilly (LLY) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The company continues to focus on its ongoing initiatives, including the expansion of its research facilities and the advancement of its pharmaceutical pipeline. Traders should monitor upcoming earnings reports and regulatory decisions for potential market-moving events.
Eli Lilly's stock drops 1.4% to $1,215.02 amid market fluctuations.
In the past 24 hours, Eli Lilly's stock experienced a 1.4% decline, closing at $1,215.02. This movement reflects broader market fluctuations rather than company-specific news.
No significant market-moving news for Eli Lilly (LLY) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The company continues to focus on its core pharmaceutical products, including Mounjaro, Zepbound, and Verzenio. Investors should monitor upcoming earnings reports and industry news for potential impacts on the stock.
No significant market-moving news for Eli Lilly (LLY) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The company continues to focus on its core pharmaceutical operations, with no major announcements or events reported.
Eli Lilly's stock (LLY) closes at $1,185.71, down 0.58% on August 7, 2026.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The stock closed at $1,185.71 on August 7, 2026, reflecting a slight decrease of 0.58% from the previous close. No major news or events have been reported during this period.
No significant market-moving news for Eli Lilly (LLY) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The company continues to focus on its core pharmaceutical operations, with no major announcements or events reported.
Eli Lilly's stock (LLY) closed at $1,191.94 on August 6, 2026, up 1.96%.
In the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The stock closed at $1,191.94 on August 6, 2026, up 1.96%. Traders should monitor upcoming earnings reports and regulatory decisions for potential market-moving events.
Eli Lilly's Q2 2026 dividend of $1.73 per share declared, payable June 10.
Eli Lilly and Company declared a quarterly dividend of $1.73 per share for Q2 2026, payable on June 10 to shareholders of record as of May 15. This announcement reflects the company's ongoing commitment to shareholder returns.
No significant market-moving news for Eli Lilly (LLY) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The company continues to focus on its existing drug portfolio and ongoing clinical trials. Investors should monitor upcoming earnings reports and industry news for potential impacts on the stock.
No significant market-moving news for Eli Lilly (LLY) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The company continues to focus on its ongoing projects and market strategies.
Eli Lilly's stock price declines 0.56% to $1,148.84 amid market fluctuations.
Over the past 24 hours, Eli Lilly's stock has experienced a slight decline of 0.56%, closing at $1,148.84. This movement reflects broader market fluctuations rather than company-specific news.
No significant market-moving news for Eli Lilly (LLY) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The company continues to focus on its ongoing initiatives, including the advancement of its oral GLP-1 receptor agonist, orforglipron, and the expansion of its research capabilities. Traders should monitor upcoming earnings reports and any announcements related to regulatory approvals or partnerships.
No significant market-moving news for Eli Lilly (LLY) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The company continues to focus on its ongoing initiatives, including the advancement of its oral GLP-1 receptor agonist, orforglipron, and the expansion of its global presence. Investors should monitor upcoming earnings reports and regulatory updates for potential impacts on the stock.
No significant market-moving news for Eli Lilly (LLY) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. Traders should monitor upcoming earnings reports and industry news for potential impacts on the stock.
No significant market-moving news for Eli Lilly (LLY) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The company continues to focus on its existing drug portfolio and strategic initiatives.
No significant market-moving news for Eli Lilly (LLY) in the past 24 hours.
Over the past 24 hours, there have been no significant developments affecting Eli Lilly's stock performance. The company continues to focus on its ongoing projects and investments.
Analysez n’importe quel graphique en quelques secondes
Voici la lecture du jour sur Eli Lilly. Pointez votre caméra vers n’importe quel graphique et ChartDetector AI vous livre une analyse technique complète en quelques secondes — gratuit sur iOS.
Généré par IA à partir de sources d'actualités publiques. Ceci n'est pas un conseil financier.